Tags · Status
needs a source
A claim in this topic has been challenged and not yet supported.
Related in this group: solved · open question · long read · beginner friendly · worked example · data table · disputed
90 topics · page 3 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A question about how this site should cite…
|
+50 | 54 | 1.4k | 11mo |
|
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…
|
+77 | 84 | 54k | 11mo |
|
Coming back to: When "no data" is the complete and final answer
When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about the compound itself rather than about a trial of it. I…
|
+77 | 82 | 12k | 11mo |
|
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. A narrow question about IGF-1, deliberately narrow, because the broad…
|
+14 | 18 | 53k | 12mo |
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…
|
+107 | 119 | 11k | 12mo |
|
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Asking about sequence verification directly, because I have…
|
+104 | 114 | 10k | 12mo |
|
Antibiotics and a course of something with delayed emptying
Antibiotics and a course of something with delayed emptying — setting out what I have, and where I think it stops being reliable. Something about antibiotics does not reconcile and I would like a second pair…
|
+99 | 108 | 1.4k | 12mo |
|
Why plausible mechanism is not evidence of effect — one year on
The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. What changes if the standard account of plausible…
|
+3 | 7 | 3.6k | 13mo |
|
Second pass at: How to research a compound with no human data without deceiving yourself
Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. The question about research a…
|
+64 | 71 | 2.5k | 13mo |
|
Insulin combinations and hypoglycaemia risk
On the subject in the title: Insulin combinations and hypoglycaemia risk Working notes rather than a conclusion. I was wrong about insulin combinations and hypoglycaemia risk in a thread last spring and I…
|
+18 | 22 | 7.8k | 13mo |
|
When a preprint is the best available evidence and we say so — a second dataset
When a preprint is the best available evidence and we say so — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. A preprint question rather than a…
|
+20 | 24 | 36k | 14mo |
|
Delayed gastric emptying and oral medication absorption: which drugs matter
On the subject in the title: Delayed gastric emptying and oral medication absorption: which drugs matter Working notes rather than a conclusion. A follow-up question about delayed gastric emptying and oral…
|
+110 | 116 | 43k | 14mo |
|
Follow-up: Tesamorelin has an approved indication — what that changes about the evidence
Posting this under the heading it deserves: Tesamorelin has an approved indication — what that changes about the evidence Everything below is what sits behind that. What changes if the standard account of…
|
+63 | 68 | 18k | 14mo |
|
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. Posting a small dataset on Ipamorelin…
|
2 | 27k | 14mo | |
|
Revisiting: Oral versus injected administration claims for BPC-157
On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. A follow-up question about Oral versus injected administration claims…
|
+23 | 27 | 7.7k | 15mo |
|
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…
|
+154 | 165 | 6.3k | 15mo |
|
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…
|
+109 | 125 | 2k | 16mo |
|
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. GHRH analogues versus ghrelin mimetics — I…
|
+9 | 13 | 249 | 17mo |
|
Anaesthesia and elective surgery: the aspiration question — does this still hold?
Anaesthesia and elective surgery: the aspiration question — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about Anaesthesia and…
|
+23 | 27 | 5.6k | 17mo |
|
Revisiting: What a well-designed human trial of a secretagogue would look like
On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Something about well-designed human trial does not reconcile…
|
+69 | 74 | 25k | 18mo |
|
Levothyroxine timing: a real interaction with a simple fix
Levothyroxine timing: a real interaction with a simple fix Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about levothyroxine timing, deliberately narrow,…
|
+20 | 24 | 60k | 18mo |
|
Coming back to: Grapefruit: why this class is not the class that cares
Posting this under the heading it deserves: Grapefruit: why this class is not the class that cares Everything below is what sits behind that. I was wrong about Grapefruit in a thread last spring and I would…
|
+44 | 48 | 12k | 18mo |
|
Follow-up: Oral contraceptives and delayed emptying: what the data shows
Oral contraceptives and delayed emptying: what the data shows — setting out what I have, and where I think it stops being reliable. A follow-up question about Oral contraceptives and delayed emptying that I…
|
+31 | 35 | 13k | 18mo |
|
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold?
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Two things I would like separated…
|
+19 | 23 | 4.2k | 19mo |
|
What would change my mind about repair peptides: a specific answer — one year on
What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…
|
+9 | 13 | 42k | 19mo |
|
[2026 update] Insulin combinations and hypoglycaemia risk
Insulin combinations and hypoglycaemia risk Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Insulin combinations and hypoglycaemia risk. It is…
|
2 | 2.8k | 20mo | |
|
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…
|
+7 | 11 | 5.5k | 20mo |
|
Why a preprint's supplementary material is often the best part
Why a preprint's supplementary material is often the best part I have a specific reason for asking rather than idle curiosity, and the context is below. A question about how this site should cite something…
|
+38 | 42 | 863 | 22mo |
|
Naming conventions for research peptides and the confusion they cause — one year on
Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. Asking about Naming conventions for research peptides…
|
+1 | 5 | 181 | 2y |
|
How this community labels and discusses unrefereed work
How this community labels and discusses unrefereed work — that is the question, and I have not found it answered plainly anywhere I have looked. Reading an unrefereed manuscript properly, and asking whether I…
|
+112 | 119 | 1.3k | 2y |